Tryptophan Metabolism and Mental Disorders (G10993)

Target Name: SDS

NCBI ID: G10993

Content of Review Report on SDS Target / Biomarker

SDS

Tryptophan Metabolism and Mental Disorders

SDS (L-threonine dehydratase), also known as tryptophan hydroxylase, is an enzyme involved in the metabolism of tryptophan, a key amino acid found in many proteins, including those involved in vision, hearing, and neurotransmitter synthesis. Mutations in the SDS gene have been linked to a range of neurological and psychiatric disorders, including autism, schizophrenia, and depression.

SDS is a protein that catalyzes the conversion of L-tryptophan to its tryptophanylated form. This conversion is a critical step in the tryptophan cycle, during which L-tryptophan is broken down and its amino acids reassembled into tryptophan. The SDS enzyme is responsible for hydroxylating the L-tryptophan molecule, which is then attached to a threonine molecule. This conversion process allows the cell to synthesize the tryptophanylated form of the amino acid, which is then involved in the synthesis of various molecules involved in cell signaling and neurotransmission.

SDS gene mutations have been linked to a range of neurological and psychiatric disorders. For example, individuals with the SDS gene mutation called SDS-ASO have been found to have an increased risk of developing autism-like symptoms, including social interaction difficulties, repetitive behaviors , and anxiety. In addition, individuals with the SDS gene mutation called SDS-10 have been found to have an increased risk of developing depression and anxiety.

SDS is also a potential drug target for several psychiatric disorders. For example, SDS has been shown to be involved in the development of symptoms of attention deficit hyperactivity disorder (ADHD), including impulsivity and hyperactivity. Additionally, SDS has been found to be involved in the development of symptoms of oppositional behavior disorder (OBS), a type of disorder characterized by persistent and persistent behavioral disorder.

In addition to its potential as a drug target, SDS is also a potential biomarker for several psychiatric disorders. For example, SDS has been shown to be involved in the development of symptoms of major depressive disorder (MDD), including low mood and anhedonia. In addition, SDS has been found to be involved in the development of symptoms of post-traumatic stress disorder (PTSD), a disorder characterized by persistent feelings of distress and avoidance after a traumatic event.

Overall, SDS is a complex enzyme that plays a critical role in the metabolism of tryptophan, a key amino acid involved in the synthesis of various molecules involved in cell signaling and neurotransmission. Mutations in the SDS gene have been linked to a range of neurological and Psychiatric disorders, including autism, schizophrenia, and depression. As such, SDS is a potential drug target and biomarker for several psychiatric disorders. Further research is needed to fully understand the role of SDS in the development and treatment of these disorders.

Protein Name: Serine Dehydratase

The "SDS Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SDS comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets